A Phase I/II Clinical Trial of "Off-the-shelf" NK Cell Administration in Combination With Allogeneic SCT to Decrease Disease Relapse in Patients With High-risk Myeloid Malignancies Undergoing Matched Related, Matched Unrelated, One Antigen Mismatched Unrelated, or Haploidentical Stem-cell Transplantation
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1/2
- Enrollment
- 24 patients (estimated)
- Sponsors
- MD Anderson Cancer Center
- Tags
- Allogeneic Stem Cell Transplant, Natural Killer (NK) Cells (Allogeneic), White Blood Cell Stimulant
- Trial Type
- Treatment
- Last Update
- 2 days ago
- SparkCures ID
- 1591
- NCT Identifier
- NCT05115630
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.